Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

1983 ◽  
Vol 143 (6) ◽  
pp. 584-590 ◽  
Author(s):  
Linda A. Baker ◽  
L. Y. Cheng ◽  
I. B. Amara

SummaryIn this double-blind, four-week study, 28 chronic schizophrenic patients receiving neuroleptic medication plus the antiparkinsonian drug, benztropine mesylate, were either switched to placebo or maintained on benztropine. Patients withdrawn from benztropine reliably increased their overall scores on the Wechsler Memory Scale in comparison with the drug group. Sub-test scores suggest that deficits in attention and concentration were induced by treatment with benztropine. Psychotio decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, but only 14.2 per cent of the placebo group experienced extrapyramidal symptoms severe enough to require resumption of benztropine therapy. It is suggested that antiparkinsonian agents should be prescribed only if and when EPS occur.


Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Lúcia de Fátima Cahino da Costa Hime ◽  
Ceci Mendes Carvalho Lopes ◽  
Cristiane Lima Roa ◽  
Lea Tami Suzuki Zuchelo ◽  
Edmund C. Baracat ◽  
...  

1996 ◽  
Vol 18 (2-3) ◽  
pp. 201-202
Author(s):  
S. Potkin ◽  
J. Zborowski ◽  
J. Wu ◽  
K. Giles ◽  
R. Bera ◽  
...  

1980 ◽  
Vol 137 (6) ◽  
pp. 522-529 ◽  
Author(s):  
J. Guy Edwards ◽  
John R. Alexander ◽  
M. S. Alexander ◽  
Alan Gordon ◽  
T. Zutchi

SummaryIn a double-blind comparative trial of sulpiride (600–1,800 mg/day) and trifluoperazine (15–45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment.


1976 ◽  
Vol 128 (5) ◽  
pp. 451-455 ◽  
Author(s):  
P. Andrews ◽  
J. N. Hall ◽  
R. P. Snaith

SummaryPhenothiazine drugs were withdrawn from 17 chronic schizophrenic in-patients, with a control group of 14 patients remaining on active medication. The trial was conducted under double blind conditions over a period of 42 weeks with weekly assessment of the patients by ward nurses. Of the placebo group 35 per cent relapsed, relapse being related to the level of previous active medication.


1988 ◽  
Vol 153 (2) ◽  
pp. 208-213 ◽  
Author(s):  
E. Goodall ◽  
Christine Oxtoby ◽  
Ray Richards ◽  
Gill Watkinson ◽  
David Brown ◽  
...  

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg d-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking d-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.


Sign in / Sign up

Export Citation Format

Share Document